| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9320310 | European Urology | 2005 | 6 Pages |
Abstract
Combination therapy using weekly paclitaxel and carboplatin was active in patients with advanced TCC and adverse prognostic features. The weekly dosing used in this trial warrants further investigation as an alternative first-line approach in patients with poor renal reserve and/or performance status or as a second-line management of advanced TCC.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Manfred Johannsen, Markus Sachs, Jan Roigas, Axel Hinke, Andrea Staack, Stefan A. Loening, Dietmar Schnorr, Andreas H. Wille,